Clinical trials recruiting in Murrieta, California

Phase breakdown

Conditions recruiting in Murrieta, California

Recruiting trials in Murrieta, California

• A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07185009 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
  NCT07165028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
  NCT06680830 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT06667076 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
  NCT06581328 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
  NCT06233461 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
  NCT06887192 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
  NCT07804615 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184931 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07184996 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
  NCT06456593 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
  NCT07228832 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Sacral Neuromodulation for Male Overactive Bladder (MOAB)
  NCT06511141 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male
• Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
  NCT07284472 · Phase: Phase 2, Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
  NCT04198766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT06029972 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• [18F]PI-2620 Phase 3 Histopathological Study
  NCT05641688 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Murrieta, California?

17 recruiting trials have at least one study site in Murrieta, California.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.